FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 中國飛鶴有限公司 呈交日期： 2025年12月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06186 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 China Feihe Limited 中國飛鶴有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6186） 須予披露交易 認購金融產品 認購金融產品 茲提述本公司日期為二零二四年十二月三十日及二零二五年九月二十四日的 公 告，內 容 有 關（其 中 包 括）本集團認購若干中信銀行的理財及結構性存款金融 產 品（「認購中信銀行金融產品」）。 董 事 會 宣 佈，於 二 零 二 五 年 十 二 月 十 六 日，本 公 司 全 資 附 屬 公 司 黑 龍 江 飛 鶴 銷 售以其閑置資金認購若干中信銀行發售的金額為人民幣700百萬元的理財金融 產 品（「認購信銀產品」）。下 表 載 列 認 購 信 銀 產 品 之 主 要 條 款： 所認購 預 期 本金金額 年收益率 | （人 民 幣 元） 產品名稱 到期日 | | ...

Core Viewpoint - The report from Feihe highlights a strong financial performance and a confident outlook for future growth, driven by its core strategy of "a new generation more suitable for Chinese babies" [2][3] Financial Performance - Feihe reported a revenue of 9.15 billion and a net profit of 1.03 billion for the first half of 2025, with cash and cash equivalents amounting to 6.48 billion, providing a solid foundation for strategic actions [2] - The company announced a share buyback plan of no less than 1 billion and an annual dividend plan totaling approximately 2 billion, reflecting management's confidence in cash flow health and optimistic future profitability [2] Strategic Initiatives - Feihe's "new generation more suitable" strategy is a comprehensive evolution focused on "fresh nutrition," addressing the upgraded consumer demand where 78% of educated mothers prioritize "active nutrition" and "good absorption" when selecting formula [3][5] - The introduction of high-end products, such as Jicui and Qicui, exemplifies this strategy, with a focus on self-researched and produced key raw materials, reducing the freshness timeline from years to within 30 days [3][5] Technological Advancements - Feihe achieved a significant technological leap with a proven 6.4 times better absorption rate and is the first in the industry to implement "raw material traceability," enhancing consumer trust through verifiable scientific data [5][7] - The company adheres to a "clinical first, market later" approach, establishing a competitive barrier through rigorous clinical trials, with products demonstrating superior performance in key immune indicators and cognitive development metrics [5][7] Market Position and Global Strategy - Feihe holds leading positions in several key metrics, including first in Chinese breast milk research and infant formula patents, which underpin its premium product matrix and market pricing power [7] - The company is expanding its global footprint, with a Canadian factory receiving the first local infant formula production license and products available in over 1,500 supermarkets, diversifying revenue streams and mitigating market risks [9] Social Responsibility and Future Outlook - Feihe's commitment to social responsibility is evident in its 1.2 billion fertility subsidy plan, expected to benefit over 800,000 newborn families, aligning corporate strategy with market investment for future user growth [9] - The synergy between the buyback and dividend plans and the "new generation more suitable" strategy creates a robust cycle of financial strength supporting ongoing research and innovation, ensuring sustained cash flow and profit growth [9][10]

Market Performance - The Hong Kong and A-share markets saw a significant rise in baby and child-related stocks, particularly in the dairy sector, with several companies hitting their daily limit up [1] - In A-shares, companies such as Huangshi Group, Junyao Health, Nanjiao Food, and Sunshine Dairy reached their daily limit, while Knight Dairy rose over 8% [1] - In Hong Kong stocks, Youran Dairy increased by over 7%, Modern Dairy by over 3%, and Mengniu Dairy by 1% [1][3] Policy Impact - The recent surge in the market is attributed to a major signal released during the National Medical Security Work Conference on December 13, which stated the goal of achieving "no out-of-pocket" expenses for childbirth within the policy scope by 2026 [3] - The government is actively implementing a series of supportive policies for childbirth, including extended maternity leave, childcare subsidies, and educational housing support, to create a more favorable environment for childbirth [4] - The implementation of a national childcare subsidy system is set to begin on January 1, 2025, providing annual subsidies of 3,600 yuan per child under three years old [4][5] Demographic Trends - The national birth population is projected to reach 9.54 million in 2024, marking the first increase since 2017, although the overall population continues to decline [8] - The birth population for 2025 is expected to range between 7 million and 8.71 million, potentially hitting a record low since 1950 [8] - The central government's focus on stabilizing the birth population indicates a commitment to enhancing fertility policies, which may lead to increased demand in the maternal and infant sectors [6][8] Industry Outlook - The new policies are expected to directly benefit sectors such as assisted reproduction and obstetric healthcare, while also providing sustained advantages to the maternal and infant consumption industry chain, including retail, food, and supplies [8] - Analysts suggest that the government's financial support and the anticipated increase in newborns will boost consumer confidence and improve demand for infant formula products [8]

Core Viewpoint - China Feihe (06186.HK) has been actively repurchasing shares, indicating strong confidence in its future growth and stability in cash flow [1][3]. Group 1: Share Buyback and Financial Strategy - On December 12, 2025, Feihe repurchased over 5.65 million shares, bringing the total repurchased shares to over 236 million, with a cumulative buyback amount exceeding 900 million HKD [1]. - In its mid-year earnings forecast on July 4, 2025, Feihe announced a plan to utilize no less than 1 billion HKD for share repurchases, targeting up to 10% of total shares [3]. - Feihe aims to maintain a stable dividend policy, expecting to distribute no less than 2 billion HKD in dividends for 2025, reflecting its robust operational cash flow [3]. Group 2: Product Innovation and Market Leadership - Feihe has maintained its position as the market leader in China's infant formula sector for six consecutive years, showcasing its role as a benchmark for high-quality development in the dairy industry [3]. - The company recently launched the "New Generation More Suitable" initiative, which includes a comprehensive upgrade across four dimensions: full industry chain, breast milk-based formula, fresh nutrition, and feeding effectiveness [3]. - Feihe introduced two new products, "Jicui" and "Qicui," which embody the "New Generation More Suitable" concept and set new freshness standards in the infant formula industry [5]. Group 3: Commitment to Social Responsibility and Innovation - Feihe has actively engaged in public welfare, contributing a total of 840 million RMB by the end of 2024, with a focus on medical, educational, and maternal-infant care initiatives [6]. - Since 2022, the company has invested over 65 million RMB in the "Support Longjiang Education Public Welfare Action," benefiting over 3.3 million teachers and students [6]. - Feihe's R&D investment has seen a compound annual growth rate of over 30% from 2018 to 2024, emphasizing its commitment to technological innovation [6].

Core Viewpoint - China Feihe (06186.HK) has been actively repurchasing shares, indicating strong confidence in its future growth and stability, alongside a commitment to maintaining dividends [4][7]. Group 1: Share Buyback and Financial Commitment - On December 12, 2025, China Feihe repurchased over 5.65 million shares, bringing the total repurchased shares to over 236 million, with a cumulative buyback amount exceeding 900 million HKD [1]. - In July 2025, the company announced a share buyback plan with a minimum of 1 billion HKD allocated for repurchases, targeting up to 10% of total shares [4]. - The company plans to maintain a stable dividend policy, expecting to distribute at least 2 billion HKD in dividends for 2025 [4]. Group 2: Market Leadership and Product Innovation - China Feihe has maintained its position as the leading brand in China's infant formula market for six consecutive years, reflecting its role as a benchmark for high-quality development in the dairy industry [4]. - The company launched a new product line, "New Generation More Suitable," which emphasizes breakthroughs in four dimensions: full industry chain, breast milk-like formula, fresh nutrition, and feeding effectiveness [4]. - The introduction of the "Fresh Nutrition System" ensures a comprehensive quality assurance system from raw milk to finished products, with 100% control over 11 core raw materials and full traceability [4]. Group 3: Social Responsibility and Technological Innovation - China Feihe has actively engaged in social responsibility initiatives, contributing 840 million CNY in donations and launching the "Support Longjiang Education Public Welfare Action," investing over 65 million CNY since 2022 [6][7]. - The company has prioritized technological innovation, with an average annual growth rate of over 30% in R&D investment from 2018 to 2024 [7]. - In 2025, China Feihe introduced "乳蛋白鲜萃提取科技" and established an international-leading database for HMOs, further enhancing its R&D capabilities [7]. Group 4: International Expansion - China Feihe is accelerating its internationalization efforts, having obtained a production license for infant formula in Canada, with products already available in over 1,500 North American retail stores [7].

Group 1 - The dairy sector in Hong Kong and A-shares experienced a collective surge, with companies like Yurun Dairy (up 9.07%) and Modern Dairy (up 5.07%) leading the gains, driven by multiple factors including market rotation, consumption recovery, and expectations around fertility policies [1] - The National Medical Security Administration announced measures aimed at achieving "no out-of-pocket" expenses for childbirth by 2026, which could lower childbirth costs and boost demand for maternal and infant dairy products [1] - The Ministry of Commerce emphasized the need for stronger collaboration between business and finance to stimulate consumption, which is expected to inject recovery momentum into the dairy sector as consumer willingness and capacity improve [2] Group 2 - The dairy industry is anticipated to undergo a cyclical reversal, with previous pressures on dairy companies' performance easing as the dairy farming sector enters a transformative phase, potentially leading to a supply-demand turning point by 2026 [3] - According to Guotai Junan Securities, the milk price has shown signs of recovery due to seasonal supply-demand mismatches, with the overall supply-demand situation improving, and domestic raw milk self-sufficiency exceeding 70% [3] - CITIC Securities noted that the average milk price in major production areas remained stable at 3.02 yuan/kg, with expectations of a price turning point approaching by 2026, which could enhance the performance of upstream dairy farming and midstream dairy companies [4] Group 3 - Investment recommendations include focusing on leading companies like Yili and Mengniu, which are at historically low valuation levels and have the potential to increase market share while ensuring shareholder returns through dividends [4] - New Dairy Industry is highlighted for its profit elasticity and alignment with current consumption trends, while Miaokelando is recognized as a leading cheese brand with promising growth prospects in the high-growth segment of dairy products [4]

Core Viewpoint - The Hong Kong stock market saw a rise in three-child policy concept stocks, driven by a recent national medical insurance conference that outlined plans to enhance maternity insurance and support for various employment groups [1] Group 1: Policy Impact - The national medical insurance conference emphasized the need to adapt to population development strategies by promoting maternity insurance and long-term care insurance by 2026 [1] - The policy aims to include flexible workers, migrant workers, and new employment forms in maternity insurance coverage [1] - There is a goal to improve the medical expense coverage for prenatal checks, aiming for "no out-of-pocket" expenses for childbirth within the policy scope nationwide [1] Group 2: Market Reaction - Stocks related to assisted reproduction and maternal and child healthcare sectors reacted positively, with companies like Jinxin Fertility rising approximately 4% [1] - Other companies such as China Feihe, Mengniu Dairy, and China Wangwang also experienced gains of 2%, 1.4%, and 0.21% respectively [2]

Group 1 - The core viewpoint of the article highlights the rise of Hong Kong stocks related to the three-child policy, indicating a positive market response to this demographic initiative [1] Group 2 - Jinxin Fertility saw an initial increase of approximately 4% in its stock price [1] - China Feihe's stock rose by 2% [1] - Mengniu Dairy experienced a stock increase of 1.4% [1] - China Wangwang also followed the upward trend [1]

Group 1 - The core viewpoint of the news is that Hong Kong stocks related to the three-child policy are experiencing an upward trend, driven by recent government policies aimed at enhancing fertility insurance and maternal healthcare [1] - The national medical insurance work conference held in Beijing emphasized the need to adapt to population development strategies by promoting the development of maternity insurance and long-term care insurance [1] - The policy aims to include flexible workers, migrant workers, and new employment forms in the coverage of maternity insurance, and to improve the medical expense coverage for prenatal checks, striving for "no out-of-pocket" expenses for childbirth within the policy scope [1] Group 2 - Analysts suggest that the new policy will directly benefit sectors such as assisted reproduction and obstetrics, while also providing sustained advantages to the maternal and infant consumption industry chain, including retail, food, and supplies [1] - Stocks of companies like Jinxin Fertility (up approximately 4%), China Feihe (up 2%), Mengniu Dairy (up 1.4%), and China Wangwang (up 0.21%) have reacted positively to the policy announcement [1][2] - Jinxin Fertility is highlighted as a leading player in the assisted reproduction sector in Hong Kong, indicating strong market confidence in the company's prospects following the policy changes [1]